This episode of Blunt Business explores a significant shift in federal drug policy following a new executive order aimed at accelerating research into psychedelics like LSD, psilocybin, and ibogaine for treating mental health disorders.
The newly signed executive order to direct the FDA to fast-track these compounds through new "National Priority" vouchers.
Beyond psychedelics, the host discusses the impact of GLP-1 weight-loss drugs (like Ozempic) on the cannabis market, noting that dispensaries are seeing a shift in consumer preference toward lower-dose products to mitigate "the munchies."